Innovative Treatments Based on Genomic Aberrations in Leukemia and Lymphoma

Dear Colleagues,

Clinical management and risk stratification of leukemia/lymphoma depend largely on hematopathology findings, identification of chromosomal abnormalities obtained using conventional cytogenetics and fluorescence in situ hybridization (FISH) testing. In the last few decades, testing algorithms have been implemented to support optimal risk-oriented therapy, leading to a large improvement in overall survival. In addition, large-scale genomic studies have identified multiple aberrations of prognostic significance that are not routinely tested by existing modalities. However, as chromosomal microarray analysis (CMA) and next-generation sequencing (NGS) technologies are increasingly used in the clinical management of hematologic malignancies, these abnormalities may be more readily detected. CMA and NGS significantly impact treatment by guiding the selection of targeted therapies, customizing chemotherapy regimens, and facilitating personalized approaches such as immunotherapy and bone marrow transplantation. These technologies allow for more precise treatment planning, ultimately improving efficacy and reducing side effects, while also aiding in monitoring minimal residual disease to predict relapse and adjust therapies accordingly.

Prof. Dr. Vera Ulrike Bacher
Dr. Ashwini K. Yenamandra
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.